{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:14:06Z","timestamp":1762150446791,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":3952,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007420","name":"Lee Hysan Foundation","doi-asserted-by":"publisher","award":["2003\/2004"],"award-info":[{"award-number":["2003\/2004"]}],"id":[{"id":"10.13039\/100007420","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.fertnstert.2011.05.085","type":"journal-article","created":{"date-parts":[[2011,7,5]],"date-time":"2011-07-05T04:10:38Z","timestamp":1309839038000},"page":"445-451.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The reproductive and metabolic effect of rosiglitazone\u00a0on Chinese women with polycystic ovarian syndrome\u2014a double-blind randomized placebo-controlled study"],"prefix":"10.1016","volume":"96","clinical-trial-number":[{"clinical-trial-number":"chictr-trc-09000670","registry":"10.18810\/chictr"}],"author":[{"given":"Po Mui","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing Hung","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald Ching","family":"Wan Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai Ping","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Hang","family":"Yuet Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Chun","family":"Yip Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis Chun","family":"Chung Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Wai","family":"Kei Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Ho","family":"Ming Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Chung","family":"Ngor Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher John","family":"Haines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2011.05.085_bib1","first-page":"3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study","volume":"83","author":"Knochenhauer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2007-1016294","article-title":"Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications","volume":"15","author":"Nestler","year":"1997","journal-title":"Semin Reprod Endocrinol"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1385\/ENDO:30:1:45","article-title":"Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS","volume":"30","author":"Teede","year":"2006","journal-title":"Endocrine"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/humrep\/dei289","article-title":"Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome","volume":"21","author":"Cataldo","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1507\/endocrj.52.299","article-title":"Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease","volume":"52","author":"Dereli","year":"2005","journal-title":"Endocr J"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1210\/jc.2004-1376","article-title":"Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance","volume":"90","author":"Sepilian","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","article-title":"Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity","volume":"82","author":"Baillargeon","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/humrep\/dei505","article-title":"Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study","volume":"21","author":"Rautio","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib10","first-page":"271","article-title":"Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome [in Chinese]","volume":"37","author":"Zheng","year":"2002","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/eje.1.02331","article-title":"Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study","volume":"156","author":"Majuri","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib12","first-page":"336","article-title":"Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria","volume":"11","author":"Lam","year":"2005","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/humrep\/den090","article-title":"Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome","volume":"23","author":"Cheung","year":"2008","journal-title":"Hum Reprod"},{"issue":"Suppl 4","key":"10.1016\/j.fertnstert.2011.05.085_bib14","first-page":"1493","article-title":"Higher metabolic risk in Chinese women fulfilling the NIH diagnostic criteria for polycystic ovarian syndrome","volume":"91","author":"Lam","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib16","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","article-title":"A critical evaluation of simple methods for the estimation of free testosterone in serum","volume":"84","author":"Vermeulen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 5","key":"10.1016\/j.fertnstert.2011.05.085_bib17","article-title":"Insulin resistance directly contributes to androgenic potential within ovarian theca cells","volume":"91","author":"Qu","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09513590500430575","article-title":"Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome","volume":"21","author":"Garmes","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib19","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonz\u00e1lez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib20","first-page":"1626","article-title":"Troglitazone improves ovulation and hirsutism in the polycystic ovary\u00a0syndrome: a multicenter, double blind, placebo-controlled trial","volume":"86","author":"Azziz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJMp078167","article-title":"The rosiglitazone story\u2014lessons from an FDA Advisory Committee meeting","volume":"357","author":"Rosen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib22","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib23","first-page":"111","article-title":"Clinical consequences of disseminating the rosiglitazone FDA safety warning","volume":"16","author":"Orrico","year":"2010","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.fertnstert.2011.05.085_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09513590410001729194","article-title":"Revisit of metformin treatment in polycystic ovarian syndrome","volume":"19","author":"Lam","year":"2004","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.fertnstert.2011.05.085_bib25","first-page":"CD003053","article-title":"Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility","author":"Tang","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib26","first-page":"515","article-title":"Experimental approaches to study PPAR gamma agonists as antidiabetic drugs. 1: Methods Find","volume":"24","author":"V\u00e1zquez","year":"2002","journal-title":"Exp Clin Pharmacol"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1210\/en.2008-1289","article-title":"Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression","volume":"150","author":"Selva","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/eje.1.01948","article-title":"Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome","volume":"153","author":"Tarkun","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1210\/jc.2004-1376","article-title":"Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance","volume":"90","author":"Sepilian","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.05.085_bib30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/humrep\/dei505","article-title":"Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study","volume":"21","author":"Rautio","year":"2007","journal-title":"Hum Reprod"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028211008715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028211008715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:09:44Z","timestamp":1762150184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028211008715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0015028211008715"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2011.05.085","relation":{},"ISSN":["0015-0282"],"issn-type":[{"type":"print","value":"0015-0282"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The reproductive and metabolic effect of rosiglitazone\u00a0on Chinese women with polycystic ovarian syndrome\u2014a double-blind randomized placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2011.05.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}